

Pr Jessica Zucman-Rossi

17th January 2022

Director of the Centre de Recherche des Cordeliers, UMRs1138, Inserm, Sorbonne Université, Université de Paris <http://www.crc.jussieu.fr/> (2019-2023) and of the team « Functional Genomics of Solid Tumors, FunGeST » <http://www.zucmanlab.com>

Professor of Medicine (PU-PH), Université de Paris-Hôpital Européen Georges Pompidou, AP-HP, Oncology department.

President of the International Liver Cancer Association (ILCA) 2021-2023

Editor in chief of JHEP Reports (2019-2023), the new gold open access journal of EASL.

Chair of the scientific orientation for research committee at Fondation ARC

Education

- 1990 Doctor in Medicine, University Paris 7, France
- 1994 Specialization in Internal Medicine (AIHP)
- 1994 PhD in life science, Fundamental Basis of Oncogenesis, University Paris 7
- 1998 Agreement for Research Direction (HDR), University Paris 7

Postgraduate Education

1987-1994: Resident in Internal Medicine, Hopitaux de Paris, in alternation with PhD. 1994-1996: Post-doctoral research Fellow in Genetic-Oncology, Institut Curie (Director: Gilles Thomas)

Major responsibilities currently and in the past 10 years

- **President of the International Liver Cancer Association (ILCA) 2021-2023**
- **Editor in chief of JHEP Reports** (2019-2023), the new gold open access journal of EASL.
- **Chair of the scientific** orientation for research committee at Fondation ARC (2021-2024)
- Member of the **FNRS committee** for physiopathology (Belgium, 2020-2022)
- Associate editor **Journal of Hepatology** (2009-2014), **Senior editor** (2014-2019)
- Editorial board of **Hepatology** (2009-2011), **Journal of Hepatology** (2005-2008), **World Journal of Gastroenterology** (2005-2007), **GCB** (2010-)
- **Chairman of the scientific committee CSS2 at Inserm** “Genetic, Epigenetic and Cancer” 2012-2016
- **Chair of the AASL SIG**

Expertise for research projects and funding for national and international institutions:

Chairman of the scientific committee CSS2 at Inserm “Genetic, Epigenetic and Cancer” 2012-2016; AERES (**Chair, IPC Marseille 2011**), AFEF, ANR, ANRS, membre CSS4 (2007-2010), Centre national de séquençage (CNS), Clinique de la souris, CNRS, Conseil général d’Aquitaine, INCa, recherche translationnelle PRTK (**chair 2008-2009**), Inserm, Ligue nationale contre le cancer (LNCC), Ministère de la Recherche Français, ligue contre le cancer, Université Paris Descartes, Fondation IGR (**Chair 2009-2011**), Fondation de France, ARC comité tumeurs (2011-2013), SAB du CRCL et CBL (2018)

Member of the FNRS committee for physiopathology (Belgium, 2020-2022), ERC advanced, Association Anglaise de recherche contre le cancer (AICR) ; Association Italienne de Recherche Contre le cancer (AIRC) ; BMRC Singapour, *Dutch Digestive Foundation*, NCCS NUHS SMC (Singapore), Cancer Research UK ; United States-Israel Binational Science Foundation (BSF) ; Dutch Cancer Society ; *FWF (Austria)*, Gouvernement chinois de Hong Kong ; the Croucher Foundation (HK) ; Israel Science Foundation (ISF) ; K.U. Leuven, Belgique ; Ministère de la Recherche italien ; Mount Sinai school of medicine ; Swiss National Science Foundation ; Swiss Cancer League, WELBIO (BE) ; ERC (EU) ; MD Anderson (US), HBMS (Singapore).

Scientific Awards and distinctions (2012-2022):

Award by the French Academy of Medicine, **Albert 1er de Monaco**, 2021
Awarded by Clarivate “**most highly cited researcher**” 2021
Docteur **Honoris Causa Université Catholique de Louvain**, Belgium 2019
Ismar Boas Medal, Germany 2019
Chevalier de la Légion d’honneur 2018,
Award **René et André Duquesne**, Comité de Paris Ligue Contre le Cancer 2018 ;
Award « Coups d’élan » **Fondation Schueller-Bettencourt**, 2016 ;
Award **Raymond Rosen**, Fondation pour la Recherche Médicale 2016 ;
Award **Charles Oberling** June 2015;
Elected fellow of the European Academy of Cancer Sciences, 2014;
Prime for excellent scientific activity (PEDR) 2012-present;
Award Inserm Research 2012

Publications summary (March 2022)

ORCID : 0000-0002-5687-0334

ISI Web of Science March 2022, H-factor = 80, Citations >33,800. 242 original articles, 92 reviews or commentaries, 10 book chapters

Google scholar March 2022, H-factor = 93, Citation > 43,000

15 Major Publications (last 5 Years)

Trépo E*, Caruso S*, Yang J*, Imbeaud S, Couchy G, Bayard Q, Letouzé E, Ganne-Carrié N, Moreno C, Oussalah A, Feray C, Blanc JF, Clément B, Hillon P, Boursier J, Paradis V, Calderaro J, Gnemmi V, Nault JC, Guéant JL, Devière J, Archambeaud I, Vitellius C, Turlin B, Bronowicki JP, Gustot T, Sutton A, the GENTHEP Consortium[§], Ziol M, Nahon P, Zucman-Rossi J* *Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study*. The **Lancet Oncology**, Dec 10:S1470-2045(21)00603-3. doi: 10.1016/S1470-2045(21)00603-3. 2021. IF=41

Hirsch TZ*, Pilet J*, Morcrette G*, Roehrig A, Monteiro BJE, Molina L, Bayard Q, Trépo E, Meunier L, Caruso S, Renault V, Deleuze JF, Fresneau B, Chardot C, Gonzales E, Jacquemin E, Guerin F, Fabre M, Aerts I, Taque S, Laithier V, Branchereau S, Guettier C, Brugières L, Rebouissou S, Letouzé E**, Zucman-Rossi J**. *Integrated genomic analysis identifies driver genes and cisplatin-resistant progenitor phenotype in pediatric liver cancer*. **Cancer Discovery**, *co-first, **co-corresponding 11(10):2524-2543. doi: 10.1158/2159-8290.CD-20-1809. Epub 2021 Apr 23. PMID: 33893148. IF=39

Péneau C, Imbeaud S, La Bella T, Hirsch TZ, Caruso S, Calderaro J, Paradis V, Blanc JF, Letouzé E, Nault JC, Amaddeo G, Zucman-Rossi J* *Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma*. **Gut**. 2021 Feb 9;gutjnl-2020-323153. doi: 10.1136/gutjnl-2020-323153. Online ahead of print. PMID: 33563643, IF=19

Ningarhari M, Caruso S, Hirsch TZ, Bayard Q, Franconi A, Védie AL, Noblet B, Blanc JF, Amaddeo G, Ganne N, Ziol M, Paradis V, Guettier C, Calderaro J, Morcrette G, Kim Y, MacLeod AR, Nault JC, Rebouissou S, Zucman-Rossi J*. *Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target*. **J Hepatol**. 74(5):1155-1166. PMID: 33338512. 2021 IF=25

Bayard Q, Caruso S, Couchy G, Rebouissou S, Bioulac Sage P, Balabaud C, Paradis V, Sturm N, de Muret A, Guettier C, Bonsang B, Copie C, Letouzé E, Calderaro J, Imbeaud S, Nault JC, Zucman-Rossi J*. *Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas*. **Gut**. 2020. Sep;69(9):1667-1676. IF=19.8

Hirsch TZ, Negulescu A, Gupta B, Caruso S, Noblet B, Couchy G, Bayard Q, Meunier L, Morcrette G, Scoazec JY, Blanc JF, Amaddeo G, Nault JC, Bioulac-Sage P, Ziol M, Beaufrère A, Paradis V, Calderaro J,



Imbeaud S, Zucman-Rossi J*. *BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA*. **J Hepatol**. 2020 May;72(5):924-93 IF=20.5

Nault JC**, Martin Y, Caruso S, Hirsch TZ, Bayard Q, Calderaro J, Charpy C, Copie-Bergman C, Ziol M, Bioulac-Sage P, Couchy G, Blanc JF, Nahon P, Amaddeo G, Ganne-Carrié N, Morcrette G, Chiche L, Duvoux C, Faivre S, Laurent A, Imbeaud S, Rebouissou S, Llovet J, Seror O, Letouzé E, Zucman-Rossi J**. *Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma*. **Hepatology**, 2019, 71:1, 164-182 IF: 14.9

Caruso S*, Calatayud AL*, Pilet J*, La Bella T, Rekić S, Imbeaud S, Letouzé E, Meunier L, Bayard Q, Rohr-Udilova N, Pénéau C, Grasl-Kraupp B, de Koning L, Ouine B, Bioulac-Sage P, Couchy G, Calderaro J, Nault JC, Zucman-Rossi J**, Rebouissou S**. *Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response*. **Gastroenterology**. 2019, 157:3, 760-776. IF=17.3

Yang J, Trépo E, Nahon P, Cao Q, Moreno C, Letouzé E, Imbeaud S, Bayard Q, Gustot T, Deviere J, Bioulac-Sage P, Calderaro J, Ganne-Carrié N, Laurent A, Blanc JF, Guyot E, Sutton A, Ziol M, Zucman-Rossi J**, Nault JC**. *A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease*. **Hepatology**. 2019. IF: 14.6

Bayard Q, Meunier L, Peneau C, Renault V, Shinde J, Nault JC, Mami I, Couchy G, Amaddeo G, Tubacher E, Bacq D, Meyer V, La Bella T, Debailon-Vesque A, Bioulac-Sage P, Seror O, Blanc JF, Calderaro J, Deleuze JF, Imbeaud S, Zucman-Rossi J**, Letouzé E**. *Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress*. **Nature communications**. 2018 Dec 7;9(1):5235. doi: 10.1038/s41467-018-07552-9.

Calderaro J, Letouzé E, Bayard Q, Boulai A, Renault V, Deleuze JF, Bestard O, Franco D, Zafrani ES, Nault JC, Moutschen M, Zucman-Rossi J*. *Systemic AA amyloidosis caused by inflammatory hepatocellular adenoma*. **The New England Journal of Medicine**, 379(12):1178-1180. 2018

Letouzé E*, Shinde J*, Renault V, Couchy G, Blanc JF, Tubacher E, Bayard Q, Bacq D, Meyer V, Semhoun J, Bioulac-Sage P, Prévôt S, Azoulay D, Paradis V, Imbeaud S, Deleuze JF, Zucman-Rossi J. *Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis*. **Nature Communications**. 2017 Nov 3;8(1):1315. *equally contributed

Rebouissou S*, Franconi A*, Calderaro J, Letouzé E, Imbeaud S, Pilati C, Nault JC, Couchy G, Laurent A, Balabaud C, Bioulac-Sage P, Zucman-Rossi J**. *Genotype-phenotype correlation of CTNNB1 mutations with different β -catenin activation levels in liver tumors*. **Hepatology**, 24, 6, 2047-2061, 2016

Nault JC, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, Letouzé E, Pilati C, Verret B, Blanc JF, Balabaud C, Calderaro J, Laurent A, Letexier M, Bioulac-Sage P, Calvo F, Zucman-Rossi J. *Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas*, **Nature Genetics**, 47(10):1187-93, 2015

Schulze K**, Imbeaud S**, Letouzé E**, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc J-F, Mazzaferro V, Calvo C, Villanueva A, Nault JC, Bioulac-Sage P, Stratton MR, Llovet JM, Zucman-Rossi J*. *Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets*. **Nature Genetics**, 47(5):505-11, 2015. **equally contributed